Replimune Says Stockholders Approved Amendment To Increase Authorized Common Shares From 150M To 300M, Effective September 15
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001737953/000110465926108243/tm2625488d1_8k.htm
Stocks · News reference
Wedbush Upgrades Replimune Group to Outperform, Raises Price Target to $19
Wedbush analyst Robert Driscoll upgrades Replimune Group (NASDAQ:REPL) from Neutral to Outperform and raises the price target from $12 to $19.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Replimune Group, Inc. (REPL)
Filed: 2026-09-16 AccNo: 0001104659-26-108243 Size: 215 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits
JP Morgan Maintains Overweight on Replimune Group, Raises Price Target to $21
JP Morgan analyst Anupam Rama maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $20 to $21.
Replimune Group Files Shelf Prospectus For Offering; Size Not Disclosed
-SEC Filing